Gardasil's China troubles haunt Merck in Q3, with execs warning of more obstacles ahead

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional fright surrounding another staple product took the spotlight during the company's earnings conference call.